Overview
========

As one participant in a recent study aptly remarked, "If I see all the side effects of the drug I am already ill" ([@B22], p. 4). Numerous studies indicate that negative health information can generate negative expectancies that lead to adverse outcomes -- labeled the nocebo effect ([@B9]; [@B14]; [@B18]). This creates an ethical paradox: informed consent requires that patients are warned about potential side effects ([@B55]; [@B11], [@B12]), but these warnings themselves may produce poorer health outcomes via the nocebo effect (e.g., [@B34]; [@B33]; [@B35]).

The burden of nocebo effects on the healthcare system is not trivial. Nocebo effects account for between 40 and 100% of drug side effects ([@B30]). Nocebo-induced side effects can result in treatment termination, protracted treatment, and psychological distress ([@B2]). Communication strategies that reduce negative expectancies associated with the nocebo effect, but preserve informed consent, are therefore critical. One strategy that is gaining increasing theoretical attention is framing (e.g., [@B57]; [@B15]; [@B40]; [@B21]; [@B53]; [@B39]).

Interest in side effect framing stems from the work of Kahneman and Tversky ([@B26]; [@B50]), who demonstrated that individuals do not appraise information purely rationally and objectively, but are influenced by how that information is presented. In their classic examples ([@B50]), shifts in preference for statistically comparable outcomes were observed when framed in terms of lives saved (positively framed) as opposed to lives lost (negatively framed). Similarly, framing of side effect information to focus on positive outcomes (e.g., likelihood of *not* experiencing side effects) rather than the negative (e.g., likelihood *of* experiencing side effects) may reduce maladaptive expectancies about side effects ([@B21]), thereby reducing the burden of nocebo side effects ([@B13]; [@B18]). A particularly appealing aspect of using framing to reduce nocebo side effects is that because statistical information regarding side effects is equivalent, informed consent is maintained.

The effects of framing on health outcomes unrelated to the nocebo effect are well-documented ([@B37], [@B38]; [@B20]). However, there appears to be surprisingly little empirical research examining whether framing can reduce nocebo-induced side effects and no attempts to synthesize existing studies. To address this, we systematically reviewed studies regarding framing and side effects, in order to identify promising framing strategies for reducing nocebo side effects and make suggestions for future research. Since only a small number of studies were identified, we present the results in narrative fashion. Full details of the search ([Figure 1](#F1){ref-type="fig"}) and methods ([Supplementary Material](#SM1){ref-type="supplementary-material"}) are provided.

![Search terms and PRISMA flow-chart (from: [@B32]) outlining the procedure used to identify studies included in review.](fphar-10-00167-g001){#F1}

Evidence to Date
================

What Constitutes Side Effect Framing?
-------------------------------------

[@B29] distinguished between three sub-types of framed information: attribute framing (valence framing of a characteristic), risky choice framing (framing of risk information), and goal framing (framing the goal of an action). Due to differentially framing a single characteristic, attribute framing is likely of greatest theoretical relevance to the nocebo effect. The single characteristic is the likelihood of experiencing the symptom, framed positively (will *not*) or negatively (*will*). However, [@B29] taxonomy precludes framing types with qualitative differences in the information presented (e.g., "message framing" below). Therefore, we opted for a broader definition and considered any manipulation in which framing was used to accentuate side effects positively, which we refer to as "positive valence framing." In all, we identified six empirical studies comparing a positive valence frame with another type of frame. [Table 1](#T1){ref-type="table"} summarizes these studies.

###### 

Summary of studies included in review.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                    Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Participants                                                                      Healthy volunteers                                                                                                                                                             Healthy volunteers                                                                  Patients with respiratory and cardiac disease                                                                                       Healthy volunteers                                                                                                    Healthy volunteers                                                                                                                  Healthy volunteers

  Sample size per group                                                             Positive Frame: 33 Negative Frame: 33                                                                                                                                          Positive Frame: 36\                                                                 Positive Frame: 148 Negative Frame: 144                                                                                             Positive Frame: 102 Negative Frame: 101                                                                               Positive Frame: 40 Negative Frame: 40                                                                                               Positive Frame: 48\
                                                                                                                                                                                                                                                                   Negative Frame: 39\                                                                                                                                                                                                                                                                                                                                                                                                                                                               Negative Frame: 51\
                                                                                                                                                                                                                                                                   Control: 37                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Control: 27

  Treatment                                                                         Active treatment 100 g Diclofenac / 1.2 mg Atropine                                                                                                                            Placebo tablet described as benzodiazepine for anxiety                              Active influenza vaccination                                                                                                        Sham treatment described as a "well known tablet"                                                                     Active treatment (beta-blocker) 100 g Metoprolol                                                                                    Sham brain stimulation (tDCS) to assess cognitive performance

  Framing Type                                                                      Message Framing                                                                                                                                                                Attribute                                                                           Attribute                                                                                                                           Attribute (with caveat)^a^                                                                                            Message Framing                                                                                                                     Attribute

  Communication method                                                              Video only                                                                                                                                                                     Verbal, written, and pictorial                                                      Verbal, written, and pictorial                                                                                                      Written only                                                                                                          Verbal only                                                                                                                         Verbal only

  Statistical Information                                                           None (verbal descriptor: "frequent")                                                                                                                                           Natural frequency                                                                   Percentage and natural frequency                                                                                                    Percentage and natural frequency                                                                                      Natural frequency                                                                                                                   Percentage

  No. of framed side effects                                                        8^b^                                                                                                                                                                           4                                                                                   5                                                                                                                                   14                                                                                                                    1^c^                                                                                                                                1

  Outcome Measure                                                                   GASE^d^                                                                                                                                                                        Modified GASE^d^                                                                    Study specific^d^                                                                                                                   Modified GASE^d^                                                                                                      Modified GASE^d^                                                                                                                    Study specific^d^

  Measured Symptoms: occurring generally vs. specifically attributed to treatment   Attributed to treatment                                                                                                                                                        Generally occurring                                                                 Generally occurring                                                                                                                 Attributed to treatment                                                                                               Attributed to treatment                                                                                                             Generally occurring

  Raw effect size data presented in the paper                                       Side effect frequency increased by 0.8 symptoms (on a 36 item GASE) in the positive frame                                                                                      Side effects reduced by 1.42 points on a 11-point GASE                              Approximately 17--19% reduction in reporting of myalgia and chills and an 8% drop in work absenteeism                               Positive framing group 34% less symptoms attributed to the tablet                                                     Reduction in the intensity of the framed side effect (dizziness) of 0.12 points (4-point GASE) associated with the positive frame   Positive framing group reported headache on 0.34 fewer recording periods (out of 5) compared to negative frame

  Descriptive Statistics (framed side effects: *M*; *SD*)                           Positive Frame (1.70; 1.44) / Negative Frame (0.91; 0.84)                                                                                                                      Positive Frame (2.46; 2.88) / Negative Frame (3.88; 2.94)                           Descriptive statistics not published: averaged effect size *r* is reported from the 3 χ^2^ values available (i.e., 8.9, 6.2, 4.3)   Number experiencing side effects (*OR* = 0.66): Positive Frame (*n* = 33; 32.4%) / Negative Frame (*n* = 47; 46.5%)   Positive Frame (0.48; 0.68) / Negative Frame (0.60; 0.63)                                                                           Positive Frame (1.28; 1.77) / Negative Frame (1.62; 1.97) / Control (0.48; 1.25)

  Largest effect size for framed side effects (Pearson's *r*)                       0.32^e^                                                                                                                                                                        0.24^e^                                                                             0.19^e^                                                                                                                             0.11^e^                                                                                                               0.09^f^                                                                                                                             0.09^e^

  No. of non-framed side effects assessed                                           None                                                                                                                                                                           22                                                                                  9                                                                                                                                   9                                                                                                                     28                                                                                                                                  None

  Largest effect size for non-framed side effects (Pearson's *r*)                   N/A                                                                                                                                                                            0.15                                                                                Not reported                                                                                                                        0.06                                                                                                                  0.15                                                                                                                                N/A

  Expectancy measure                                                                Expectancy for relief, not side effects, measured                                                                                                                              Single-item, study specific^g^                                                      Six items, study specific^g^                                                                                                        None                                                                                                                  None                                                                                                                                None

  Effect of frame on Expectancy (Pearson's *r*)                                     N/A                                                                                                                                                                            0.17                                                                                0.10^h^                                                                                                                             N/A                                                                                                                   N/A                                                                                                                                 N/A

  Anxiety Measure                                                                   STAI and ASI^i^                                                                                                                                                                STAI^i^                                                                             None                                                                                                                                STAI Short^i^                                                                                                         None                                                                                                                                None

  Effect of Anxiety                                                                 No difference between groups (STAI *r* = 0.06, *p* = 0.61; ASI *r* = 0.12, *p* = 0.32). ASI associated with more medication attributed side effects (*r* = 0.30, *p* = 0.02)   No overall difference in anxiety between framing groups (*r* = -0.05, *p* = 0.68)   N/A                                                                                                                                 Increase in anxiety associated with more side effects in negative frame (*r* = 0.02, *p* = 0.04)                      N/A                                                                                                                                 N/A
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a

Statistical presentation type and written descriptors differed by frame.

b

Eight frequently reported side effects are listed during consent. Wording of the positive frame was "if you experience a side effect, you might take this as a reminder that the analgesic medication is active," suggesting all side effects are positive (unlike

Wilhelm et al., 2018

). Side effects are measured via the Generic Assessment of Side Effects Scale (GASE) (see below) and not split into framed and non-framed categories.

c

One side effect (dizziness) was framed as positive, four were listed during consent, and eight treatment-specific side effects were statistically analyzed \[those considered frequent in the patient information leaflet (PIL)\]. As our primary interest is the direct effect of framing on side effects, we focus on side effect intensity for the framed side effect (dizziness).

d

GASE (

Rief et al., 2011

). The GASE is a 36-item scale assessing the experience of symptoms. The scale is rated on a 4-point likert scale (11-point in

Faasse et al., 2018a

) and can be used to assess intensity of general symptoms as well as frequency and intensity of symptoms attributed to treatment. Headache frequency in

Caplandies et al. (2017)

was rated on a 5-point scale and embedded among eight other symptoms. Symptom measurement in

O'Connor et al. (1996)

is based on

Scheifele et al. (1990)

but not reported in detail in either paper.

e

Consistent with other health-related framing reviews (e.g.

O'Keefe and Jensen, 2007

,

2009

;

Gallagher and Updegraff, 2012

), Pearson's r was used as a summary effect size. As difference between values are small, effect sizes are used only as a tool to generate discussion. We note that difference in experimental procedures and measured variables can generate extraneous fluctuations in standardized effect sizes (

Baguley, 2009

). We therefore we urge against strong conclusions. Primary effect sizes are calculated for framed symptoms (i.e., those listed during the consent process). As experiments did not report statistically significant results across all outcome measures, the largest effect size pertaining to either side effect intensity or frequency is listed with description.

f

For consistency, we report the effect size for change in side effect intensity of the framed side effect (dizziness) in the case of

Wilhelm et al. (2018)

. We note that the largest effect in this paper is perceived threat of eight drug-specific side-effects (r = 0.18). As only one these side effects was framed, and half not listed during consent, this effect does not form the primary focus of the present article.

g

Wording of the expectancy item in

Faasse et al. (2018a)

was: "how likely are you to experience side effects as a result of taking the benzodiazepine tablet?" (11-point scale). In

O'Connor et al. (1996)

, perceived vaccine risks and benefits (flu, systemic and local side effects) were rated on a 21-point probability scale (0--100%).

h

The largest effect size associated with a single item of

O'Connor et al.'s (1996)

expectancy measure was the expectancy for acquiring local side effects, which differed by 11% between frames (positive 35.6% vs. negative 46.6%).

i

The State-Trait Anxiety Inventory (

Spielberger, 1983

) is a 20-item questionnaire assessing state anxiety. The short version of the scale (

Marteau and Bekker, 1992

) contains six items. The Anxiety Sensitivity Index (

Reiss et al., 1986

) is a sixteen-item questionnaire assessing beliefs that the experience of anxiety has negative implications. All measures employ a 4-point scale.

Attribute Framing
-----------------

Four of the six studies identified investigated attribute framing. As above, attribute framing involves identical statistical information being presented either positively (will *not* experience) or negatively (*will* experience). [@B36] was the first and the only one involving a clinical sample. They compared positive and negative attribute framing regarding influenza vaccines in patients with respiratory and cardiac disease. Patients were provided with verbal, written, and pictorial information regarding side effect risk, presented in a positive (60% will *not* get a sore arm) or negative (40% *will* get a sore arm) attribute frame. Three days post intervention, the positive frame led to fewer reported side effects and less absence from work than the negative frame, indicating a significant framing effect.

[@B54] administered placebo tablets to healthy volunteers described as a well-known medication. Information about multiple possible side effects (e.g., headache, nausea) was framed positively (will *not* be affected) or negatively (*will* be affected) as part of a Patient Information Leaflet (PIL). They implemented a hurdle model (see: [@B24]) on side effects attributed to the treatment and found that fewer participants reported such side effects following the positive frame. However, number and severity of side effects in those reporting at least one did not differ between frames, suggesting the positive frame primarily affected any occurrence of side effects. Worth also noting, their study does not meet strict criteria for attribute framing ([@B29]). While side effect risk was framed positively or negatively, statistical presentation type and written descriptors differed by frame (e.g., headache as an "uncommon side effect, 80% *will not* be affected" vs. as a "very common side effect, more than 1 in 10 *will* be affected;" [@B51]), which may have influenced results.

[@B16] administered placebo tablets under the guise of a benzodiazepine and were the only researchers to include a no treatment control. Information about four side effects presented verbally, in writing, and pictorially was either framed positively (will *not* experience) or negatively (*will* experience). Both frames produced nocebo side effects relative to control. The positive frame reduced side effect reporting relative to the negative frame 15 min after treatment, but not 24 h later, suggesting temporary success of the framing manipulation.

[@B5] were the only researchers to include a no-framing instruction control. They delivered sham brain stimulation to healthy volunteers to induce headaches in a 2 (effect type framing: primary or side effect) × 2 (attribute framing: positive vs. negative) + 1 (no-frame control) design. Participants received a verbal warning about headaches framed either positively (30% *unlikely* to get headache) or negatively (70% *likely* to get a headache), unless assigned to the control, where they received no information regarding side effects. There was an overall nocebo effect relative to control and these nocebo headaches were more likely in primary effect condition compared to side effect condition. However, unlike the above studies, there was no significant attribute framing effect on any measure.

### Positive Message Framing

Two studies employed positive message framing, involving information that side effects were indicative of the drug working ([@B56]; [@B19]).

[@B56] administered the beta-blocker metoprolol to healthy volunteers and verbally framed dizziness as a positive (indicative of the drug working) or negative occurrence (common unpleasant side effect). Framing had no effect on the frequency or intensity of side effects, but trended toward reducing perceived threat of side effects (Pearson's *r* = 0.18). Exploratory moderation analysis revealed a reduction in frequency and threat of side effects among a subset of participants (those with high harm beliefs) -- but we focus here on the overall sample to ensure consistency across studies.

[@B19] administered the analgesic diclofenac with a side-effect-inducing agent (atropine) in healthy volunteers. Video instructions stated that experiencing side effects were an indication that the medication was active in the body and would help reduce pain (positive frame) or simply to inform staff if side effects were experienced (control frame). In this case, the positive frame led to more treatment-attributed side effects, but lower overall side effect intensity. Further, in the positive frame, side effect frequency predicted increased analgesia suggesting the positive frame may bolster treatment efficacy via the placebo effect for those who experience side effects.

Summary
-------

Taken together, three of four studies suggest that positive attribute framing produces small reductions in side effects (effect size range: *r* = 0.11--0.24). In terms of message framing, the results were less consistent, with one study showing mixed effects (increased attribution, but decreased intensity) and the other only showing trends toward reduced side effect threat (i.e., not attribution or intensity).

Methodological Considerations and Future Directions
===================================================

While the handful of existing studies suggest that framing is a promising technique for reducing nocebo side effects, they also highlight several unanswered questions that need to be addressed before the widespread use of framing can be recommended.

What Is the Best Mode of Communication?
---------------------------------------

The studies reviewed varied in terms of the mode of communication of side effect warnings. Two studies employed written, verbal, and pictorial methods simultaneously ([@B36]; [@B16]), two used verbal ([@B5]; [@B56]), one video ([@B19]), and one written only ([@B54]). The data in [Table 1](#T1){ref-type="table"} suggest that the studies using multiple modes (including video, which comprises visual and verbal presentation methods) elicited numerically larger framing effect sizes, suggesting that multi-modal presentation may more successfully elicit the framing effect. Of course, it is impossible to know whether pictorial methods alone or interactions between multiple methods are fundamental to driving the framing effect. Regardless, traditional methods of delivering side effect information, such as in PILs, may be limited for inducing framing effects because they involve a single, written communication mode. Emerging health technologies ([@B46]; [@B10]), however, make the multi-media delivery of health information increasingly easy to implement. Thus, future research could capitalize on such techniques and systematically examine the effect of framing in different communication modes. This would help determine the optimal mode of delivery for inducing framing effects and to overcome potentially less efficacious methods (e.g., written PILs).

What Is the Best Method of Presenting Statistical Information About Side Effects?
---------------------------------------------------------------------------------

Framed information regarding side effect prevalence can be presented in a number of formats, ranging from verbal descriptors (e.g., "common"), natural frequencies (1 in 10) and percentages (10%). Each influences the perception of absolute perceived risk of side effects to varying degrees (e.g., [@B23]; [@B58]; [@B4]), potentially impacting the nocebo effect. Of the studies reviewed, one employed verbal descriptors ([@B19]), one percentages ([@B5]), two natural frequencies ([@B16]; [@B56]), and two both percentages and natural frequencies ([@B36]; [@B54]). Interpretation of the effects of statistical presentation was difficult in two studies. One employed percentages and natural frequencies separately across frames, potentially confounding the framing effect with altered perceptions of risk ([@B54]). The other framed dizziness as either a positive or neutral consequence of treatment, but employed negative attribute framing (symptoms *occur* in 10 out of 100 people) in both cases ([@B56]). Of the remaining, the largest framing effect was associated with verbal descriptors, followed by natural frequencies ([@B16]). As outlined in the subsequent section, inclusion of statistical information is advised to reduce the perception of side effect risk ([@B28]). If the available data holds, then natural frequencies may be the optimal method of eliciting a framing effect.

An additional related factor concerns the number of side effects that patients are warned about. Evidence suggests that side effect warnings are better remembered, and nocebo side effects stronger, when fewer potential symptoms are listed ([@B6]). Due to limitations on memory capacity, framing may therefore only be effective when warnings contain few side effects. This is difficult to deduce from the studies reviewed. Among those employing an attribute frame and reporting an effect, the number of listed side effects decreased as effect size increased. It is possible therefore, that limited memory for specific side effects weakens the framing effect, although more research is needed. One possible strategy to address this, would be to positively frame the overall likelihood of experiencing *any* side effects (as in, [@B19]), which may increase the salience of the positive frame, even with long lists of side effects.

How Does Framing Influence the Perceived Absolute Risk of Side Effects?
-----------------------------------------------------------------------

An important ethical issue regarding the use of framing strategies to reduce the nocebo effect, concerns whether framing influences the perceived absolute likelihood of side effects. That is, if positive framing led to an underestimation of the absolute risk of side effects, then one could argue that informed consent was not actually being maintained because participants are not understanding the objective risk of side effects.

[@B36] was the only study identified that examined perceived absolute risk of side effects. In their study, side effects were framed either negatively or positively according to their prevalence rates in the general population and participants were required to rate their perception of risk prior to treatment. Interestingly, both types of frames were associated with an increased perception of absolute risk relative to that outlined in the informed consent process. Importantly, estimates following the positive frame were closest to the objective statistical information -- a finding consistent with studies risk perception following framing manipulations outside the nocebo effect ([@B25]).

[@B36] findings are, therefore, encouraging in terms of suggesting that positive framing does not compromise informed consent via a perceived underestimation of the absolute risk of side effects. However, given that it was the only study to test this in the context of nocebo side effects, we recommend that future studies investigating the effect of framing on side effects also incorporate an assessment of absolute risk perception as a matter of course so that researchers and clinicians can be confident that framing is not undermining informed consent.

What Mechanisms Underlie the Framing Effect?
--------------------------------------------

Expectancy is believed to play a key role in the development of the nocebo effect (e.g., [@B18]; [@B27]). Only two studies identified examined expectancy for side effects. One found that positive framing reduced side effect expectancy ([@B36]) and one found no such effect ([@B16]). However, despite being identified as a robust predictor of the nocebo effect ([@B52]), the precise psychological mechanisms through which expectancy gives rise to adverse side effects remains unresolved.

One line of evidence suggests that negative expectancies may elicit the nocebo effect by generating anticipatory anxiety ([@B3]; [@B13]; [@B7]). This anticipatory anxiety has been proposed to generate increased attention toward internal bodily states and therefore adverse symptoms ([@B13]). This is consistent with attentional theories outside of the placebo effect, such as chronic pain (e.g., [@B48]), where anxiety regarding the threat of pain leads to interpretation of pain as harmful, increasing the attentional focus on pain. Meta-analyses of attentional processes confirm biases toward sensory pain-related stimuli in patients with pain ([@B49]). Since, risk information can be processed by affective and cognitive systems ([@B44]), we posit that positive framing attenuates anticipatory anxiety via the affective path, which in turn inhibits the nocebo effect by reducing the attention directed toward the aversive symptoms in question.

In terms of the studies identified, two provided data relevant to a possible role of anticipatory anxiety. [@B54] found that increased levels of anxiety were associated with elevated symptoms in the negative frame and [@B19] reported a positive association between increased anxiety and side effects across groups. [@B16] also measured anxiety, but this was the primary outcome for their placebo manipulation, not a possible mediator of framing. [@B54] results are consistent with evidence that side effect information delivered in PILs (typically negatively attribute framed) induce anxiety and fear in patients, particularly when many side effects are presented ([@B22]). Thus, as with assessing perceived absolute risk, we recommend that future studies examining framing and nocebo side effects explore expectancy, anxiety, and attentional biases in order to determine whether these processes underlie the framing effect.

General Issues to Do With Research on the Nocebo Effect
-------------------------------------------------------

In addition to the specific issues regarding framing and side effects described above, there are three general issues regarding nocebo research that should be considered when evaluating framing effects. First, only two studies reviewed included control groups to assess natural history ([@B16] and no-frame instruction ([@B5]) conditions. Such control groups are important for determining the extent to which framing strategies influence side effects above and beyond processes such as the Hawthorne effect, including whether the framing effect generalizes to other symptoms. Second, only one study assessed how long the framing effect lasts ([@B16]). This is important, as nocebo effects are known to be easily instated, but resistant to extinction ([@B8]; [@B7]; [@B17]). Third, inconsistent techniques were used for measuring side effects, including modified versions of the Generic Assessment of Side Effects Scale (GASE; [@B42]) and study-specific items (see [Table 1](#T1){ref-type="table"}). This lack of consistency makes cross-study comparisons difficult because the outcomes are not necessarily equivalent. Thus, as with nocebo effect research in general, we recommend that where possible future studies on framing and side effects incorporate appropriate control groups, evaluate the duration of any framing effects, develop and implement standardized measures to assess side effects, and consider potential methodological limitations when designing experiments (e.g., blinding, randomization and power: see [Supplementary Material](#SM1){ref-type="supplementary-material"}). Finally, preliminary evidence suggests that attribute and positive message framing may differentially impact side effect reporting, with the former decreasing, and the latter potentially increasing, side effect frequency. Further research is needed to disentangle these differences. Greater attention should also be paid to comparing the ability of these frame-types to uphold consent, ensuring that any intervention implemented is ethical.

Conclusion
==========

The handful of available studies suggests that positive valence framing of side effect warnings is a promising technique for reducing nocebo side effects, whilst maintaining informed consent. While the mechanisms are currently unknown, we propose that positive framing reduces anticipatory anxiety and subsequent attention to aversive symptoms, which then attenuates nocebo effects. Future research is, however, required to determine the optimal method of delivering such interventions, including the mode of delivery and statistical presentation of the side effects. Given that positive framing is relatively simple and cheap to implement, it has the potential to be a highly cost-effective technique for reducing the huge burden caused by nocebo effects.
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